Please ensure Javascript is enabled for purposes of website accessibility

Boston Scientific Stock Rises on Sales Increase, Positive Management Outlook

By Jim Crumly – Apr 29, 2020 at 5:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

But a sharp decline in medical procedures caused a drop in first-quarter profits.

A slowdown in medical procedures due to the COVID-19 pandemic caused a decline in first-quarter profits at medical device maker Boston Scientific (BSX -1.02%), but the company still managed a small sales gain, and management made encouraging comments about the future in its earnings call Wednesday. In response to the report and the commentary, shares rose almost 4%.

Sales grew 2% to $2.54 billion, and were up 3.2% excluding the effect of foreign currency moves. But adjusted earnings per share fell 20% to $0.28. Analysts had been expecting the company to earn $0.31 per share on sales of $2.52 billion.

Stethoscope with a graph in the background.

Image source: Getty Images.

Boston Scientific said on the conference call that its business in the first two months of the year had been consistent with its expectations, which were for sales growth  of 10% to 12%. But sales dropped quickly in mid-March as hospitals and clinics canceled most procedures that could be delayed in order to conserve vital medical resources for fighting the pandemic and protecting healthcare workers from COVID-19.

Further, management noted, revenue in April was down 45% to 50% year over year. The company's cardiovascular business ended Q1 with a 5.5% sales gain, medical/surgical sales grew 1.1%, and rhythm and neurological sales, which support procedures that are more easily delayed, fell 7.2%.

Boston Scientific is cutting costs aggressively, but expressed confidence that the cuts won't affect its competitiveness. Management noted that two-thirds of its business is related to procedures done in out-patient settings, and it believes that the medical providers that perform them will recover more quickly than hospitals. The company refrained from giving specific guidance, but said it believes it will return to growth in the fourth quarter.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Boston Scientific Corporation Stock Quote
Boston Scientific Corporation
BSX
$38.90 (-1.02%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.